Carestream Molecular Imaging, a division of Carestream Health, has signed an exclusive, multi-year worldwide agreement with OncoVision (Valencia, Spain), to sell, market and service Albira PET/SPECT/CT imaging system for small animal research.
Carestream Molecular Imaging expects to offer the broadest portfolio of pre-clinical in vivo imaging modalities in the market, with the addition of the multimodal imaging system. The system is expected to be introduced at the American Association of Cancer Research (AACR) Annual Meeting in Washington DC.
The Albira system features a modular architecture that introduces a patented single-crystal detector and associated electronics for rapid acquisition and reconstruction of highly resolved quantitative PET and SPECT images. The approach contrasts with the pixelated crystal technology used in most current PET and SPECT systems today.
Albira’s multimodal imaging technology is designed for pre-clinical researchers in academic, government, pharmaceutical, biotechnology and independent medical laboratories. With the new technology, scientists will advance their research into developing new predictive imaging biomarkers, accelerate the preclinical validation of new drugs, and enable the selection of drug candidates for clinical translation to speed up the drug discovery process.
Benlloch, founder and professor of Superior Council of Scientific Research, Valencia, Spain at OncoVision, said: “Albira offers unprecedented sensitivity and resolution allowing scientists to visualize metabolic processes and structures in small living animals. It is the technology of the future made reality.”
John Dellisanti, president of Carestream Molecular Imaging, said: “With the addition of the Albira system, in combination with Carestream Molecular Imaging’s high-resolution optical and X-ray systems, we offer the global research community the most innovative and extensive imaging product portfolio in the market. We are excited about our new partnership with OncoVision and the innovation that we bring to the market today, and what lies ahead in the future.”